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for Children With 
Inflammatory Bowel 
Disease
To the Editor: We read with interest 
the article entitled “Serologic Status 
of Routine Childhood Vaccines, 
Cytomegalovirus, and Epstein-Barr 
Virus in Children With Inflammatory 
Bowel Disease” by deBruyn et al., par-
ticularly the section on hepatitis B 
(HBV) seroprotection. We conducted 
a similar study in our US tertiary care 
center, analyzing HBV seroprotection 
in 159 children with inflammatory 
bowel disease (IBD) age 0–22 who re-
ceived the three-dose HBV primary se-
ries and had been exposed to a biologic 
agent. In our study, only 26% (41/159) 
of patients had HBV seroprotection 
[hepatitis B surface antibody (HBsAb) 
≥10 IU/L], compared to 71% (82/115) 
of patients in the deBruyn et  al. study 
(Table 1). Previously reported HBV 
seroprotection rates in pediatric patients 
with IBD have shown similar heteroge-
neity, ranging from 28% to 59%.1, 2 The 
difference may be partially explained by 
regional variation in vaccine timing, as 
HBV vaccination occurs during grade 
school in Canada (the deBruyn study) 
versus infancy in the USA. Because 
seroprotection wanes with time, earlier 
vaccination may manifest as lower titers 
by adolescence. While the deBruyn 
study included patients who were not re-
ceiving biologics, our study included only 
patients exposed to biologics and could 
thus represent a more immunocompro-
mised population. Immunocompromise 
may impair HBV immunity because of 
poor T-cell response, although future 
studies exploring T-cell mediated im-
mune memory in pediatric patients with 
IBD are needed.3
After identifying patients with 
inadequate HBV seroprotection, it 
is important to consider revaccina-
tion strategies. Our group evaluated 
response to a single HBV booster by 
analyzing serum HBsAb titers fol-
lowing one booster dose. We found that, 
among the 33 patients who received one 
booster dose followed by titer recheck, 
79% (26/33) of patients achieved sero-
conversion. We additionally evaluated 
response to complete booster vaccina-
tion, defined as receipt of three boosters 
or documented seroconversion before 
three boosters. These results showed 
that 98% (58/59) of patients achieved 
seroprotection after complete booster 
vaccination (Table 1). Overall, these 
data suggest that booster vaccination is 
effective for achieving seroconversion in 
this population. Adult IBD studies also 
suggest that nonresponders, after one 
HBV booster, may convert after subse-
quent boosters. Cossio-Gil et al. found 
that of 53 initial nonresponders, 53% 
responded to a second booster, whereas 
Gisbert et  al. found that of 95 initial 
nonresponders, 42% responded to a 
second booster.4, 5 Thus, checking titers 
after each booster and providing further 
vaccines only as needed may prevent un-
necessary vaccination while achieving 
seroprotection. Such efforts may help 
optimize HBV protection in children 
with IBD.
Erica J. Brenner, MD*,  
Ravi Jhaveri, MD†, 
Michael D. Kappelman, MD, 
MPH*, and Ajay S. Gulati, 
MD*
Key Words: hepatitis B, seroprotection, 
 revaccination, booster, pediatric, inflamma-
tory bowel disease
*University of North Carolina Department
of Pediatric Gastroenterology, Chapel Hill, North 
Carolina, USA; †Feinberg School of Medicine 
Department of Pediatric Infectious Diseases, Chicago, 
Illinois, USA 
Supported by: The authors have no sources of 
support to disclose.
Address correspondence to: Erica J.  Brenner, 
MD, 333 S.  Columbia Street, 247 MacNider Hall 
CB #7229, Chapel Hill, NC 27514 (Erica.Brenner@
unchealth.unc.edu).
REFERENCES
1. Watts  A, Bennett  WE, Molleston  JP, et  al.
Incidence of low seroimmunity to hepatitis B
virus in children with inflammatory bowel disease. 
J Pediatr Gastroenterol Nutr. 2017;65:551–554.
2. Yeo SJ, Lee HS, Jang BI, et al.; Crohn’s and Colitis 
Association in Daegu-Gyeongbuk (CCAiD).
Nonimmunity against hepatitis B virus infection
in patients newly diagnosed with inflammatory
bowel disease. Intest Res. 2018;16:400–408.
3. Banatvala JE, Van Damme P. Hepatitis B vaccine 
– do we need boosters? J Viral Hepat. 2003;10:1–6.
4. Cossio-Gil  Y, Martínez-Gómez  X, Campins-
Martí M, et al. Immunogenicity of hepatitis B vac-
cine in patients with inflammatory bowel disease
and the benefits of revaccination. J Gastroenterol
Hepatol. 2015;30:92–98.
5. Gisbert  JP, Villagrasa  JR, Rodríguez-
Nogueiras A, et al. Efficacy of hepatitis B vacci-
nation and revaccination and factors impacting
on response in patients with inflammatory bowel
disease. Am J Gastroenterol. 2012;107:1460–1466.
applyparastyle "fig//caption/p[1]" parastyle "FigCapt"
TABLE 1. Hepatitis B Surface Antibody Titers Before and After Hepatitis B 
Booster Vaccination in Pediatric Patients With Inflammatory Bowel Disease
Inadequate Titers Adequate Titers
(HBsAb < 10 IU/L) 
(%)
(HBsAb ≥ 10 
IU/L) (%) 
After primary series (n = 159) 118 (74) 41 (26)
After one HBV booster (n = 33) 7 (21) 26 (79)
After complete HBV revaccination 
(n = 59)
1 (2) 58 (98)
Abbreviations: HBV, hepatitis B; HBsAb, hepatitis B surface antibody.
